Immunic Gains Vital European Patent for Vidofludimus Calcium, Ensuring Market Exclusivity
- Immunic has secured a crucial European patent for vidofludimus calcium, ensuring exclusivity until at least 2038.
- This patent strengthens Immunic's intellectual property against competitors in developing therapies for multiple sclerosis and other conditions.
- The robust patent portfolio positions Immunic to attract investments and enhance partnerships for new therapy developments.
Immunic Secures Key European Patent for Vidofludimus Calcium, Strengthening Its Intellectual Property Portfolio
Immunic, Inc. announces the granting of a crucial European patent, EP3713554, for its lead treatment, vidofludimus calcium (IMU-838). This newly acquired patent from the European Patent Office (EPO) encompasses label-relevant dosing regimens applicable to multiple indications, including multiple sclerosis (MS). The patent ensures that Immunic maintains exclusive rights to vidofludimus in Europe until at least 2038, with the possibility of a Supplementary Protection Certificate (SPC) extending this exclusivity to 2043. Such protective measures are vital for a late-stage biotechnology firm like Immunic, focused on developing innovative oral therapies for neurologic and gastrointestinal conditions.
This patent complements a previously granted U.S. patent from the United States Patent and Trademark Office (USPTO) and covers all forms of vidofludimus, including its salts, solvates, and the free acid. CEO Daniel Vitt highlights that this patent plays a significant role in Immunic's intellectual property strategy, which consists of multiple layers of protection tailored to ensure market exclusivity across different formulations and therapeutic indications. With the intellectual property framework shielding its product until at least 2041 in the United States and 2039 in Europe, Immunic is poised to maximize its competitive advantage following potential regulatory approvals.
The robust patent portfolio surrounding vidofludimus also includes inventions related to its composition-of-matter, treatment protocols for relapsing and progressive forms of MS, and specific dosing strategies. Such extensive patent protections are expected to fortify Immunic’s market position in the burgeoning field of MS therapies, ultimately supporting the continued advancement of therapies for patients afflicted by such debilitating diseases. As immunotherapies gain traction, the newly acquired patent underscores Immunic's commitment to safeguarding its innovations while responding to pressing patient needs.
In addition to its strategic patent grants, Immunic's ongoing research and development efforts focus on pioneering therapies that can transform treatment landscapes. With a solid intellectual property base, the company aims to attract investment and foster partnerships that can enhance its capabilities in bringing new therapies to market. The successful acquisition of these patents reflects Immunic's proactive approach to securing its innovations and the potential benefits they bring to patients and the broader healthcare community.